According to Zacks, “Neos Therapeutics, Inc. is engaged in developing, manufacturing and commercializing products for the treatment of attention deficit hyperactivity disorder using drug delivery technologies. Its product candidates include NT-0102 methylphenidate XR orally disintegrating tablet for the treatment of ADHD; NT-0202 amphetamine XR orally disintegrating tablet for the treatment of ADHD; NT-0201 amphetamine XR liquid suspension for the treatment of ADHD and Generic Tussionex, which are in different clinical development stage. Neos Therapeutics, Inc. is headquartered in Grand Prairie, Texas. “
A number of other analysts have also commented on the company. ValuEngine lowered Zosano Pharma from a buy rating to a hold rating in a report on Wednesday, May 1st. Cantor Fitzgerald reiterated an overweight rating and set a $130.00 price target (up from $116.00) on shares of Zoetis in a report on Wednesday, June 12th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating to the stock. The stock currently has an average rating of Hold and a consensus price target of $7.00.
NEOS stock opened at $1.45 on Thursday. Neos Therapeutics has a twelve month low of $1.13 and a twelve month high of $6.94. The company has a debt-to-equity ratio of 41.70, a quick ratio of 1.27 and a current ratio of 1.49. The firm has a 50 day moving average of $1.39.
Neos Therapeutics (NASDAQ:NEOS) last posted its earnings results on Thursday, May 9th. The company reported ($0.15) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.22) by $0.07. The company had revenue of $14.63 million during the quarter, compared to the consensus estimate of $14.20 million. Equities research analysts anticipate that Neos Therapeutics will post -0.61 EPS for the current fiscal year.
A number of institutional investors have recently modified their holdings of the stock. Nantahala Capital Management LLC bought a new stake in Neos Therapeutics during the fourth quarter worth $7,400,000. BlackRock Inc. lifted its holdings in Neos Therapeutics by 28.8% during the fourth quarter. BlackRock Inc. now owns 2,733,411 shares of the company’s stock worth $4,510,000 after acquiring an additional 610,660 shares during the period. Sphera Funds Management LTD. lifted its holdings in Neos Therapeutics by 164.7% during the fourth quarter. Sphera Funds Management LTD. now owns 2,201,697 shares of the company’s stock worth $3,633,000 after acquiring an additional 1,370,000 shares during the period. Northern Trust Corp lifted its holdings in Neos Therapeutics by 71.9% during the fourth quarter. Northern Trust Corp now owns 514,618 shares of the company’s stock worth $849,000 after acquiring an additional 215,241 shares during the period. Finally, Geode Capital Management LLC lifted its holdings in Neos Therapeutics by 41.4% during the fourth quarter. Geode Capital Management LLC now owns 367,496 shares of the company’s stock worth $606,000 after acquiring an additional 107,627 shares during the period. Institutional investors and hedge funds own 54.87% of the company’s stock.
About Neos Therapeutics
Neos Therapeutics, Inc, a pharmaceutical company, develops, manufactures, and commercializes products for the treatment of attention deficit hyperactivity disorder (ADHD) using its drug delivery technology platform. Its products are extended-release (XR) medications in orally disintegrating tablets or liquid suspension dosage forms.
Further Reading: How is the discount rate different from the Federal Funds rate?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Neos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.